The APOBEC Protein Family: United by Structure, Divergent in Function

Trends in Biochemical Sciences

Volumn 41, Issue 7, 2016, Pages 578-594

  Salter, Jason D ^a   Bennett, Ryan P ^a   Smith, Harold C ^a,b  

^a OyaGen Inc   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

APOBEC; cytidine deaminase; disease mechanisms; DNA mutation; epigenetics; RNA editing

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 2; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 4; CYTIDINE DEAMINASE; DNA; GENOMIC DNA; HYDROLASE; NUCLEIC ACID; RNA; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE;

CARCINOGENESIS; CATALYSIS; CELL MIGRATION; CYTOPLASM; DNA VIRUS; ENZYME ACTIVITY; ENZYME BINDING; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; RNA BINDING; RNA EDITING; RNA TRANSCRIPTION; RNA VIRUS; CHEMISTRY; METABOLISM;

APOBEC DEAMINASES; HUMANS;

EID: 84976412149     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2016.05.001     Document Type: Review

References (144)

1. 1 Smith, H.C., RNA and DNA Editing. 2008, John Wiley & Sons.
2. 2 Chen, S.H., et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ- specific in-frame stop codon. Science 238 (1987), 363–366.
3. 3 Powell, L.M., et al. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 50 (1987), 831–840.
4. 4 Rogozin, I.B., et al. Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID–APOBEC family cytosine deaminase. Nat. Immunol. 8 (2007), 647–656.
5. 5 Conticello, S.G., The AID/APOBEC family of nucleic acid mutators. Genome Biol., 9, 2008, 229.
6. 6 LaRue, R.S., et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83 (2009), 494–497.
7. 7 Teng, B., et al. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260 (1993), 1816–1819.
8. 8 Jarmuz, A., et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79 (2002), 285–296.
9. 9 Muramatsu, M., et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 1999. 274 (1999), 18470–18476.
10. 10 Li, Z., et al. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev. 18 (2004), 1–11.
11. 11 Dickerson, S.K., et al. AID mediates hypermutation by deaminating single stranded DNA. J. Exp. Med. 197 (2003), 1291–1296.
12. 12 Honjo, T., et al. AID: how does it aid antibody diversity?. Immunity 20 (2004), 659–668.
13. 13 Papavasiliou, F.N., Schatz, D.G., Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 109:Suppl. 1 (2002), S35–S44.
14. 14 Sheehy, A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002), 646–650.
15. 15 Smith, H.C., APOBEC3G: a double agent in defense. Trends Biochem. Sci. 36 (2011), 239–244.
16. 16 Refsland, E.W., et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nuc. Acids Res. 38 (2010), 4274–4284.
17. 17 Harris, R.S., et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003), 803–809.
18. 18 Revy, P., et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 102 (2000), 565–575.
19. 19 Aydin, H., et al. Structure-guided analysis of the human APOBEC3–HIV restrictome. Structure 22 (2014), 668–684.
20. 20 Hultquist, J.F., et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85 (2011), 11220–11234.
21. 21 Rogozin, I.B., et al. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 4 (2005), 1281–1285.
22. 22 Conticello, S.G., et al. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22 (2005), 367–377.
23. 23 Okuyama, S., et al. Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. Int. J. Cancer 130 (2012), 1294–1301.
24. 24 Sato, Y., et al. Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy. J. Biol. Chem. 285 (2010), 7111–7118.
25. 25 Ortiz, M. et al. Patterns of evolution of host proteins involved in retroviral pathogenesis. Retrovirology 3, 11.
26. 26 Sawyer, S.L., et al. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol., 2, 2004, E275.
27. 27 Munk, C., et al. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol. Biol., 12, 2012, 71.
28. 28 Etienne, L., et al. The role of the antiviral APOBEC3 gene family in protecting chimpanzees against lentiviruses from monkeys. PLoS Pathog., 11, 2015, e1005149.
29. 29 Schumann, G.G., APOBEC3 proteins: major players in intracellular defence against LINE-1-mediated retrotransposition. Biochem. Soc. Trans. 35:Pt 3 (2007), 637–642.
30. 30 Koning, F.A., et al. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83 (2009), 9474–9485.
31. 31 Peng, G., et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110 (2007), 393–400.
32. 32 Stopak, K.S., et al. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282 (2007), 3539–3546.
33. 33 Rose, K.M., et al. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J. Biol. Chem. 279 (2004), 41744–41749.
34. 34 Sarkis, P.T., et al. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J. Immunol. 177 (2006), 4530–4540.
35. 35 Anderson, B.D., Harris, R.S., Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-beta/RUNX axis. Sci. Adv., 1, 2015, e1500296.
36. 36 Desimmie, B.A., et al. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J. Mol. Biol. 426 (2014), 1220–1245.
37. + T cells and macrophages. J. Virol. 87 (2013), 444–453.
38. 38 Sakurai, D., et al. APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese. Immunogenetics 67 (2015), 253–257.
39. 39 Refsland, E.W., et al. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet., 10, 2014, e1004761.
40. 40 Naruse, T.K., et al. APOBEC3H polymorphisms and susceptibility to HIV-1 infection in an Indian population. J. Hum. Genet. 61 (2015), 263–265.
41. 41 OhAinle, M., et al. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4 (2008), 249–259.
42. 42 Yu, Q., et al. APOBEC3B and APOBEC3 C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279 (2004), 53379–53386.
43. 43 Wang, T., et al. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3 C. Virology 377 (2008), 71–79.
44. 44 Bonvin, M., et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43 (2006), 1364–1374.
45. 45 Bulliard, Y., et al. Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J. Virol. 85 (2011), 1765–1776.
46. 46 Thielen, B.K., et al. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J. Biol. Chem. 285 (2010), 27753–27766.
47. 47 Sharma, S., et al. APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages. Nat. Commun., 6, 2015, 6881.
48. 48 Bransteitter, R., et al. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 4102–4107.
49. 49 Nonaka, T., et al. Carboxy-terminal domain of AID required for its mRNA complex formation in vivo. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 2747–2751.
50. 50 Smith, H.C., et al. Functions and regulation of the APOBEC family of proteins. Semin. Cell Dev. Biol. 23 (2012), 258–268.
51. 51 Yang, Y., Smith, H.C., Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing. Proc. Natl. Acad. Sci. U.S.A. 94 (1997), 13075–13080.
52. 52 Ito, S., Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 1975–1980.
53. 53 Sowden, M.P., et al. The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors. J. Cell Sci. 115 (2002), 1027–1039.
54. 54 Methot, S.P., et al. Consecutive interactions with HSP90 and eEF1A underlie a functional maturation and storage pathway of AID in the cytoplasm. J. Exp. Med. 212 (2015), 581–596.
55. 55 Bennett, R.P., et al. Nuclear exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding. J. Biol. Chem. 283 (2008), 7320–7327.
56. 56 Zhen, A., et al. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS ONE, 7, 2012, e38771.
57. 57 Gallois-Montbrun, S., et al. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81 (2007), 2165–2178.
58. 58 Wichroski, M.J., et al. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog., 2, 2006, e41.
59. 59 McDougall, W.M., Smith, H.C., Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity. Biochem. Biophys. Res. Commun. 412 (2011), 612–617.
60. 60 Wu, X., et al. Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells. Blood 112 (2008), 4675–4682.
61. 61 Dorsett, Y., et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc–Igh translocation. Immunity 28 (2008), 630–638.
62. 62 Takizawa, M., et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J. Exp. Med. 205 (2008), 1949–1957.
63. 63 Hersberger, M., et al. Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting. Biochem. J. 369:Pt 2 (2003), 255–262.
64. 64 Yamanaka, S., et al. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Genes Dev. 11 (1997), 321–333.
65. 65 Saraconi, G., et al. The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol., 15, 2014, 417.
66. 66 Lackey, L., et al. APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 419 (2012), 301–314.
67. 67 Burns, M.B., et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494 (2013), 366–370.
68. 68 Henderson, S., Fenton, T., APOBEC3 genes: retroviral restriction factors to cancer drivers. Trends Mol. Med. 21 (2015), 274–284.
69. 69 Vieira, V.C., et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio, 2014, 5.
70. 70 Land, A.M., et al. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J. Biol. Chem. 288 (2013), 17253–17260.
71. 71 Caval, V., et al. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage. Nat. Commun., 5, 2014, 5129.
72. 72 Chan, K., et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47 (2015), 1067–1072.
73. 73 Prochnow, C., et al. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445 (2007), 447–451.
74. 74 Krzysiak, T.C., et al. APOBEC2 is a monomer in solution: implications for APOBEC3G models. Biochemistry 51 (2012), 2008–2017.
75. 75 Chen, K.M., et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452 (2008), 116–119.
76. 76 Furukawa, A., et al. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J. 28 (2009), 440–451.
77. 77 Harjes, E., et al. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J. Mol. Biol. 389 (2009), 819–832.
78. 78 Byeon, I.J., et al. NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. Nat. Commun., 4, 2013, 1890.
79. 79 Kouno, T., et al. Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat. Struct. Mol. Biol. 22 (2015), 485–491.
80. 80 Kitamura, S., et al. The APOBEC3 C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 19 (2012), 1005–1010.
81. 81 Holden, L.G., et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456 (2008), 121–124.
82. 82 Shandilya, S.M., et al. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18 (2010), 28–38.
83. 83 Lu, X., et al. Crystal Structure of DNA cytidine deaminase ABOBEC3G catalytic deamination domain suggests a binding mode of full-length enzyme to single-stranded DNA. J. Biol. Chem. 290 (2015), 4010–4021.
84. 84 Shi, K., et al. Crystal structure of the DNA deaminase APOBEC3B catalytic domain. J. Biol. Chem. 290 (2015), 28120–28130.
85. 85 Bohn, M.F., et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 21 (2013), 1042–1050.
86. 86 Siu, K.K., et al. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun., 4, 2013, 2593.
87. 87 Nakashima, M., et al. Structural Insights into HIV-1 Vif–APOBEC3F Interaction. J. Virol. 90 (2015), 1034–1047.
88. 88 Wedekind, J.E., et al. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem. 281 (2006), 38122–38126.
89. 89 Betts, L., et al. Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J. Mol. Biol. 235 (1994), 635–656.
90. 90 Polevoda, B., et al. RNA binding to APOBEC3G induces the disassembly of functional deaminase complexes by displacing single-stranded DNA substrates. Nuc. Acids Res. 43 (2015), 9434–9445.
91. 91 Rathore, A., et al. The local dinucleotide preference of APOBEC3G can be altered from 5′-CC to 5′-TC by a single amino acid substitution. J. Mol. Biol. 425 (2013), 4442–4454.
92. 92 Marx, A., et al. Zinc enhancement of cytidine deaminase activity highlights a potential allosteric role of loop-3 in regulating APOBEC3 enzymes. Sci. Rep., 5, 2015, 18191.
93. 93 Bohn, M.F., et al. The ssDNA mutator APOBEC3A is regulated by cooperative dimerization. Structure 23 (2015), 903–911.
94. 94 Logue, E.C., et al. A DNA sequence recognition loop on APOBEC3A controls substrate specificity. PLoS ONE, 9, 2014, e97062.
95. 95 Navarro, F., et al. Complementary function of the two catalytic domains of APOBEC3G. Virology 333 (2005), 374–386.
96. 96 Iwatani, Y., et al. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80 (2006), 5992–6002.
97. 97 Shlyakhtenko, L.S., et al. APOBEC3G interacts with ssDNA by two modes: AFM studies. Sci. Rep., 5, 2015, 15648.
98. 98 Salter, J.D., et al. A hydrodynamic analysis of APOBEC3G reveals a monomer–dimer–tetramer self-association that has implications for anti-HIV function. Biochemistry 48 (2009), 10685–10687.
99. 99 McDougall, W.M., et al. Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes. J. Biol. Chem. 286 (2011), 30655–30661.
100. 100 Shlyakhtenko, L.S., et al. Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J. Biol. Chem. 286 (2011), 3387–3395.
101. 101 Anant, S., et al. Apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J. Biol. Chem. 270 (1995), 14762–14767.
102. 102 Prohaska, K.M., et al. The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions. Wiley Interdiscip. Rev. RNA 5 (2014), 493–508.
103. 103 Friew, Y.N., et al. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology, 6, 2009, 56.
104. 104 Huthoff, H., Malim, M.H., et al. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81 (2007), 3807–3815.
105. 105 Navaratnam, N., et al. Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition. J. Mol. Biol. 275 (1998), 695–714.
106. 106 Galloway, C.A., et al. APOBEC-1 complementation factor (ACF) forms RNA-dependent multimers. Biochem. Biophys. Res. Commun. 398 (2010), 38–43.
107. 107 Maris, C., et al. NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor. RNA 11 (2005), 173–186.
108. 108 Oka, K., et al. Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1 leads to increased low density lipoprotein in mice. J. Biol. Chem. 272 (1997), 1456–1460.
109. 109 Lau, P.P., et al. Cloning of an Apobec-1-binding protein that also interacts with apolipoprotein B mRNA and evidence for its involvement in RNA editing. J. Biol. Chem. 272 (1997), 1452–1455.
110. 110 Lau, P.P., et al. Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene. Proc. Natl. Acad. Sci. U.S.A. 91 (1994), 8522–8526.
111. 111 Bhagwat, A.S., et al. Is AID a monomer in solution?. DNA Repair (Amst) 7 (2008), 349–350 author reply 351–352.
112. 112 Brar, S.S., et al. Activation-induced deaminase, AID, is catalytically active as a monomer on single-stranded DNA. DNA Repair (Amst) 7 (2008), 77–87.
113. 113 Li, J., et al. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. J. Mol. Biol. 426 (2014), 1296–1307.
114. 114 Chaudhuri, J., et al. Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 430 (2004), 992–998.
115. 115 Svarovskaia, E.S., et al. Human APOBEC3G is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279 (2004), 35822–35828.
116. 116 Wang, T., et al. Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J. Mol. Biol. 375 (2008), 1098–1112.
117. 117 Huthoff, H., et al. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog., 5, 2009, e1000330.
118. 118 Chelico, L., et al. A structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 285 (2010), 16195–16205.
119. 119 Shlyakhtenko, L.S., et al. Atomic force microscopy studies of APOBEC3G oligomerization and dynamics. J. Struct. Biol. 184 (2013), 217–225.
120. 120 Chelico, L., et al. Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364 (2009), 583–593.
121. 121 Salter, J.D., et al. Structural insights for HIV-1 therapeutic strategies targeting Vif. Trends Biochem. Sci. 39 (2014), 373–380.
122. 122 Richards, C., et al. The binding interface between human APOBEC3F and HIV-1 Vif elucidated by genetic and computational approaches. Cell Rep. 13 (2015), 1781–1788.
123. 123 Greeve, J., et al. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J. Lipid Res. 34 (1993), 1367–1383.
124. 124 Smith, H.C., et al. Mammalian C to U editing. Top. Curr. Biol. 12 (2005), 365–400.
125. 125 Davidson, N.O., et al. Proposed nomenclature for the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme: APOBEC-1. RNA, 1, 1995, 3.
126. 126 Fossat, N., et al. C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47. EMBO Rep. 15 (2014), 903–910.
127. 127 Blanc, V., et al. Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality. Mol. Cell. Biol. 25 (2005), 7260–7269.
128. 128 Hirano, K., et al. Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. J. Biol. Chem. 271 (1996), 9887–9890.
129. 129 Skuse, G.R., et al. The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. Nuc. Acids Res. 24 (1996), 478–485.
130. 130 Rosenberg, B.R., et al. Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3′ UTRs. Nat. Struct. Mol. Biol. 18 (2011), 230–236.
131. 131 Anant, S., Davidson, N.O., An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3′ untranslated region of c-myc increases mRNA stability. Mol. Cell. Biol. 20 (2000), 1982–1992.
132. 132 Cappione, A.J., et al. A potential role for NF1 mRNA editing in the pathogenesis of NF1 tumors. Am. J. Hum. Genet. 60 (1997), 305–312.
133. 133 Mukhopadhyay, D., et al. C–U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. Am. J. Hum. Genet. 70 (2002), 38–50.
134. 134 Pery, E., et al. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83 (2009), 2374–2381.
135. 135 Anwar, F., et al. Footprint of APOBEC3 on the genome of human retroelements. J. Virol. 87 (2013), 8195–8204.
136. 136 Kinomoto, M., et al. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nuc. Acids Res. 35 (2007), 2955–2964.
137. 137 Bogerd, H.P., et al. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nuc. Acids Res. 34 (2006), 89–95.
138. 138 Chen, H., et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16 (2006), 480–485.
139. 139 Muckenfuss, H., et al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281 (2006), 22161–22172.
140. 140 Stenglein, M.D., Harris, R.S., APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281 (2006), 16837–16841.
141. 141 Chiu, Y.L., et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 15588–15593.
142. 142 Hulme, A.E., et al. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390 (2007), 199–205.
143. 143 Esnault, C., et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433 (2005), 430–433.
144. 144 Letko, M., et al. Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G J. Virol. 87 (2013), 11861–11871.